Tatiana Novobrantseva
Chief Scientific Officer NextPoint Therapeutics
Seminars
Wednesday 16th September 2026
Industry Leaders Panel Discussion:
8:30 am
- Using a SWOT analysis approach, what are the strengths, weaknesses, opportunities and threats of bispecifics/ multispecifics compared to other drug modalities?
- In which cases are bispecifics/multispecifics being prioritized for autoimmune and immunology versus oncology?
- What datapoints are being assessed when it comes to bispecifics/multispecifics from a data package perspective for approval and backing from pharma?
- What data is lacking across the board for bispecifics/multispecifics?
- How are novel versus derisked targets being assessed, and what weighting/value is placed on safety and efficacy data, versus other data points?
- What stimulates interest around bispecific/multispecific assets versus platform technologies that generate target, construct and format menus?
Wednesday 16th September 2026
The New Frontier of Solid Tumor TCEs: Achieving High Potency & Safety with B7-H7 Targeting
9:00 am
- B7-H7 is broadly upregulated across multiple high-prevalence malignancies with significant unmet need, while maintaining a restricted and favorable expression profile in healthy tissue
- NextPoint lead T-cell engager, NPX372, features an optimized molecular architecture specifically designed to achieve an expansive therapeutic index
- Leveraging a biomarker-driven patient selection strategy and validated preclinical safety data, a streamlined Phase I clinical program has been launched
